Skip to content
value.today

Pharmacyclics: financial analysis

Ratios worked out from 5 fiscal years of Pharmacyclics's statements, compared with 665 companies in Biotechnology.

The newest statement on file is for fiscal 2014. The figures below describe that year, not Pharmacyclics today.

Operating margin, 2014
16.8%
Biotechnology: -60.5%
Return on equity, 2014
11.8%
Biotechnology: -61.0%
Revenue growth, 3 years a year, 2014
345.9%
Biotechnology: 12.9%
Free cash flow margin, 2014
23.3%
Biotechnology: -61.5%

Pharmacyclics scorecard#

Passes 10 of the 12 checks that could be worked out: strongest in growth (4 of 4), weakest in profitability (3 of 5). Fiscal year 2014.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 4
    • ✓Revenue grew in the newest year180.5%Revenue up 180.5% in fiscal 2014.
    • ✓Revenue up more than 5% a year over three years345.9%345.9% a year over the three years to fiscal 2014.
    • ✓Faster growth over three years than its peers' median345.9%345.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year1.10 vs 0.87Diluted EPS 1.10 in fiscal 2014 against 0.87 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 5
    • ✓Profitable in the newest year$86 MNet income $86 M in fiscal 2014.
    • ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2014.
    • ✓Operating margin above its peers' median16.8%16.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%11.8%11.8% in fiscal 2014.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier16.8%16.8% in fiscal 2014 against -429.8% in 2011.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.23 at the end of fiscal 2014.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2014.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2014.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2014 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Revenue has grown 3 years in a row.

Worth a look

  • Receivables grew 482% while revenue grew 180%: customers are paying later, or sales were booked ahead of cash.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

4of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseno
  • Asset turnover roseyes

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin11.8%Asset turnover0.80×Assets to equity1.25×Return on equity11.8%

Profitability#

Pharmacyclics: profitability by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Gross margin94.5%98.7%———74.8%87%
Operating margin16.8%37.6%14.5%-429.8%-167.7%-60.5%85%
Net margin11.8%25.8%14.6%-427.7%-161.3%-68.9%81%
Return on equity11.8%17.6%10.3%-41.8%-22.5%-61.0%91%
Return on assets9.4%13.6%7.2%-30.3%—-44.4%92%

Growth#

Pharmacyclics: growth by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Revenue growth180.5%217.3%896.2%-11.6%—15.8%91%
Revenue growth, 3 years a year345.9%203.5%———12.9%100%
Net income growth28.5%458.9%———10.1%61%
Earnings per share growth26.4%411.8%———7.6%64%

Financial strength#

Pharmacyclics: financial strength by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Current ratio5.23×8.45×11.24×8.04×—4.39×56%
Equity share of assets78.2%81.6%60.3%87.4%—64.7%66%

Cash#

Pharmacyclics: cash by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Free cash flow$170 M$70 M$83 M$-23 M$-16 M$-40 M95%
Free cash flow margin23.3%27.1%101.4%-284.6%-168.5%-61.5%90%
Cash conversion213.4%132.5%718.0%——72.6%86%
Capital spending share of revenue1.9%7.0%3.6%14.0%2.4%1.7%—

Shareholder returns#

Pharmacyclics: shareholder returns by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Change in share count1.4%6.2%21.1%24.1%—17.3%83%

Efficiency#

Pharmacyclics: efficiency by fiscal year
Fiscal yearTrend20142013201220112010Median of peersAhead of
Asset turnover0.80×0.53×0.49×0.07×—0.26×89%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Pharmacyclics's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Pharmacyclics is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Pharmacyclics